FDA Needs Four More Weeks to Review MannKind's Diabetes Drug

The FDA has requested four additional weeks to review MannKind's experimental drug Afrezza.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!